Grifols SA (GRFS) Upgraded at Zacks Investment Research
Zacks Investment Research upgraded shares of Grifols SA (NASDAQ:GRFS) from a sell rating to a buy rating in a research note issued to investors on Wednesday morning. They currently have $18.00 price objective on the stock.
According to Zacks, “Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain. “
Separately, Morgan Stanley reaffirmed a sell rating on shares of Grifols SA in a research report on Monday, June 6th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $20.25.
Shares of Grifols SA (NASDAQ:GRFS) opened at 15.90 on Wednesday. The stock has a market capitalization of $21.73 billion, a price-to-earnings ratio of 36.05 and a beta of 0.92. Grifols SA has a 52 week low of $14.07 and a 52 week high of $18.04. The firm’s 50-day moving average is $16.19 and its 200-day moving average is $16.04.
Several institutional investors have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. increased its position in Grifols SA by 22.0% in the second quarter. PNC Financial Services Group Inc. now owns 6,870 shares of the company’s stock worth $114,000 after buying an additional 1,239 shares in the last quarter. Societe Generale acquired a new position in Grifols SA during the second quarter worth about $139,000. SG Americas Securities LLC acquired a new position in Grifols SA during the second quarter worth about $139,000. Quantbot Technologies LP increased its position in Grifols SA by 3,328.7% in the second quarter. Quantbot Technologies LP now owns 8,366 shares of the company’s stock worth $139,000 after buying an additional 8,122 shares in the last quarter. Finally, Walleye Trading LLC increased its position in Grifols SA by 31.0% in the second quarter. Walleye Trading LLC now owns 9,300 shares of the company’s stock worth $155,000 after buying an additional 2,200 shares in the last quarter. Hedge funds and other institutional investors own 20.18% of the company’s stock.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Grifols SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Grifols SA and related companies with MarketBeat.com's FREE daily email newsletter.